Lessons from the last pandemic point the way toward universal flu vaccines

Strong immune responses to unchanging, conserved parts of the 2009 H1N1 pandemic flu virus suggest strategies for effective universal vaccines
University of Chicago Medical Center

Newswise — A new study from the University of Chicago and Scripps Research Institute shows that during the last great pandemic—2009’s H1N1 influenza pandemic—people developed strong, effective immune responses to stable, conserved parts of the virus. This suggests a strategy for developing universal flu vaccines that are designed to generate those same responses, instead of targeting parts of the virus that tend to evolve rapidly and require a new vaccine every year. 

Influenza is an elusive and frustrating target for vaccines. There are two main types of flu virus that can infect humans, which evolve rapidly from season to season. When developing seasonal flu vaccines, health officials try to anticipate the predominant variation of the virus that will circulate that year. These predictions are often slightly off. Sometimes new, unexpected variants emerge, which means the vaccine may not be very effective. To avoid this, the ultimate goal of many flu researchers is to develop a universal vaccine that can account for any virus strain or variation in a given year, or even longer. 

The new study, published June 2 in Science Translational Medicine, was led by UChicago immunologists Jenna Guthmiller, PhD, and Patrick Wilson, PhD, along with structural biologists Julianna Han, PhD, and Andrew Ward, PhD, from Scripps Research Institute. They studied the immune responses of people who were first exposed to the 2009 H1N1 pandemic flu virus, either from infection or a vaccine. 

The researchers saw that the immune systems of these people recalled memory B cells from their childhood that produced broadly neutralizing antibodies against highly conserved parts on the head of a protein called hemagglutinin (HA) — a virus surface protein that attaches to receptors on host cells. These antibody responses were very effective at combatting the virus, and because they targeted conserved parts of the HA protein—meaning they don’t change very often—they could provide an enticing target for a vaccine to generate those same robust immune responses. 

In a separate 2020 study, Guthmiller and colleagues found so-called polyreactive antibodies that can bind to several conserved sites on the flu virus. Now, the new study reveals more details about the conditions that can recall the same strong immune responses as this first exposure. 

“That’s the exciting thing about this study,” Guthmilller said. “Not only have we found these broadly neutralizing antibodies, but now we know of a way to actually induce them.”

The only problem is that on subsequent encounters with the virus or a vaccine, the body doesn’t generate those same super-effective antibodies. Instead, for reasons that are unclear, the immune system tends to target newer variations on the virus. That may be effective at the time, but isn’t very helpful down the road when another, slightly different version of influenza comes along.

“When people encounter that virus a second or third time, their antibody response is pretty much completely dominated by antibodies against those more variable parts of the virus,” Guthmiller said. “So that's the uphill battle that we continue to face with this.”

The trick to getting around this is to design a vaccine that recreates that initial encounter with H1N1, using a version of the HA protein that keeps the conserved, powerful antibody-inducing components, and replaces the variable parts with other molecules that won’t distract the immune system. 

“Structural studies were essential to delineate the conserved areas on the HA protein,” said Han, who was co-first author of the new study and received her doctorate from the Committee on Microbiology at UChicago. “Now these data can be used to fine-tune vaccine targets.”

In roughly the past century, two of the four flu pandemics have been caused by H1N1 influenza, including the 1918 Spanish flu pandemic that killed as many as 100 million people. Yet the findings of this study are reassuring in the fight against possible future pandemics caused by other H1 viruses.

“The odds of there being another pandemic within our lifetime caused by an H1 virus is quite high,” Guthmiller said. “Just knowing that we actually have the immune toolkit ready to protect ourselves is encouraging. Now it's just a matter of getting the right vaccine to do that.”

The study, “First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes,” was supported by the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and GlaxoSmithKline. Additional authors include Lei Li, Olivia Stovicek, Micah E. Tepora, Henry A. Utset, Dalia J. Bitar, Natalie J. Hamel, Siriruk Changrob, Nai-Ying Zheng, Min Huang, Christopher T. Stamper, and Haley L. Dugan from the University of Chicago; and Alec W. Freyn, Sean T.H. Liu, Florian Krammer, Raffael Nachbagauer, and Peter Palese from Icahn School of Medicine at Mount Sinai.

SEE ORIGINAL STUDY



Filters close

Showing results

110 of 6123
Released: 4-Aug-2021 5:05 PM EDT
Canadian-Led International Study: Full-Dose Blood Thinners Benefit Moderately Ill COVID-19 Patients
University of Manitoba

The investigators discovered that in moderately ill patients full-dose heparin reduced the need for organ support compared to those who received lower-dose heparin.

Released: 4-Aug-2021 4:00 PM EDT
CDC withdrawing its request for emergency use authorization for its COVID-19 PCR diagnostic test does not mean the test failed
Newswise

Social media is now rife with claims about why the CDC is withdrawing its request for emergency use authorization for its COVID-19 PCR diagnostic test after December 2021.

Newswise: Public
Released: 4-Aug-2021 2:05 PM EDT
A Study Reveals What Triggers Lung Damage During COVID-19
The Korea Advanced Institute of Science and Technology (KAIST)

A KAIST immunology research team found that a specific subtype of macrophages that originated from blood monocytes plays a key role in the hyper-inflammatory response in SARS-CoV-2 infected lungs, by performing single-cell RNA sequencing of bronchoalveolar lavage fluid cells.

Released: 4-Aug-2021 1:00 PM EDT
American Society of Anesthesiologists and Anesthesia Patient Safety Foundation Say Preoperative Testing for COVID-19 is Essential, Regardless of Vaccination
American Society of Anesthesiologists (ASA)

All patients undergoing non-emergency surgeries or procedures should continue to have preoperative polymerase chain reaction (PCR) testing for SARS-CoV-2, irrespective of vaccination status, according to an updated guidance from the American Society of Anesthesiologists and Anesthesia Patient Safety Foundation.

Newswise: FAU Expert Answers Questions about Delta Variant, Vaccines and Public Safety
Released: 4-Aug-2021 12:35 PM EDT
FAU Expert Answers Questions about Delta Variant, Vaccines and Public Safety
Florida Atlantic University

Florida Atlantic University’s Joanna Drowos, D.O., M.P.H., M.B.A., Schmidt College of Medicine, provides answers to some of the most frequently asked questions regarding the COVID-19 Delta variant, vaccines and public safety measures.

Released: 4-Aug-2021 11:15 AM EDT
Rehabilitation Nurses Play Critical Role in Treating Patients with Long-Term Covid-19 Symptoms
Association of Rehabilitation Nurses

A new and free webinar from the Association of Rehabilitation Nurses (ARN) and the American Nurses Association (ANA) features advice from rehabilitation nurses to the greater nursing community about care priorities and interventions for long haul COVID-19 patients.

Newswise:Video Embedded spreading-doses-of-hope-as-covid-19-cases-rise
VIDEO
Released: 4-Aug-2021 10:35 AM EDT
Spreading ‘Doses of Hope’ as COVID-19 Cases Rise
Cedars-Sinai

In an emotional new series of videos, Black medical professionals plead for viewers to get a COVID-19 vaccine.

Newswise:Video Embedded american-college-of-surgeons-urges-surgeons-to-talk-it-up-with-patients-about-covid-19-vaccination
VIDEO
Released: 4-Aug-2021 10:00 AM EDT
American College of Surgeons Urges Surgeons to “Talk It Up” with Patients About COVID-19 Vaccination
American College of Surgeons (ACS)

ACS is launching a “Talk It Up” campaign to help surgeons address patient concerns and help them understand the importance of getting vaccinated against COVID-19.

28-Jul-2021 11:15 AM EDT
LEDs Light the Way to Coronavirus Disinfection
American Institute of Physics (AIP)

LEDs are commonly used for sterilization, and in the continued effort to combat the coronavirus pandemic, LEDs can also help inactivate SARS-CoV-2. A team in Pakistan designed far-ultraviolet LEDs at a targeted wavelength of 222 nanometers, chosen both for its ability to inactivate the virus and for being safe on human skin. They based their design on the material aluminum gallium nitride, part of a set of materials called III-nitrides which are efficient, inexpensive, and environmentally friendly.


Showing results

110 of 6123

close
1.35286